for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Orphazyme A/S

ORPH.OQ

Latest Trade

4.75USD

Change

-0.03(-0.63%)

Volume

176,131

Today's Range

4.75

 - 

4.92

52 Week Range

4.64

 - 

77.77

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.78
Open
4.90
Volume
176,131
3M AVG Volume
23.40
Today's High
4.92
Today's Low
4.75
52 Week High
77.77
52 Week Low
4.64
Shares Out (MIL)
34.95
Market Cap (MIL)
1,090.51
Forward P/E
-1.76
Dividend (Yield %)
--

Next Event

Orphazyme A/S Annual Shareholders Meeting

Latest Developments

More

Orphazyme Announces Restructuring To Focus Resources On Supporting A Path Forward For Arimoclomol In NPC

Orphazyme Provides Regulatory Update From FDA On Arimoclomol For Niemann-Pick Disease Type C

Orphazyme Announces Data From Pivotal Trial Of Arimoclomol In ALS

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Orphazyme A/S

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Industry

Biotechnology & Drugs

Contact Info

Ole Maaloees Vej 3, Copenhagen N

2200

Denmark

https://www.orphazyme.com/

Executive Leadership

Georges Gemayel

Chairman of the Board

Christophe Bourdon

Chief Executive Officer

Bo Jesper Hansen

Deputy Chairman of the Board

Anders Fink Vadsholt

Chief Financial Officer

Thomas Kirkegaard Jensen

Chief Scientific Officer

Key Stats

5.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (DKK)

2018

-11.500

2019

-16.870

2020

-22.320

2021(E)

-17.680
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.74
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.40
LT Debt To Equity (MRQ)
5.43
Return on Investment (TTM)
-164.34
Return on Equity (TTM)
-126.24

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up